Registration
|
08:40 - 09:20 |
Welcome note from MarketsandMarkets
|
09:20 - 09:25 |
Opening Remarks from the Chairperson
Michela Chiappalone , Associate Professor, University of Genova
|
09:25 - 09:30 |
Keynote Presentation: Neuroprotective therapeutics: from monomodal to multimodal strategies
Alan Palmer, Chief Executive Officer, Elixa MediScience, UK
|
09:30 - 10:00 |
CRACKING THE CODE OF NEURODEGENERATION: GROUNDBREAKING APPROACHES TO UNPRECEDENTED THERAPIES |
Systemic inflammation induced by lipopolysaccharide modulates Alzheimer’s disease progression
Marie Christine Pardon, Assistant Professor in Translational Neuroscience, University of Nottingham
|
10:00 - 10:30 |
Parkinson’s disease : alpha-synuclein toxicity and spreading, in vitro and in vivo models.
Dr. Noelle Callizot, Chief Scientific Officer, Neuro-Sys
|
10:30 - 11:00 |
Morning Refreshments and Poster Presentation | One-to-One Networking Meetings
|
11:00 - 11:40 |
Patient-Led Discovery of Disease-Relevant Antibodies and Targets
Paulina Kolasinska-Zwierz, Principal Scientist, Alchemab Therapeutics
|
11:40 - 12:10 |
Alzheimer’s Diseases: Translational Models and Brain-on-Chip innovations
Dr. Jerome Bernard, Chief Business Officer, ETAP-Lab
|
12:10 - 12:40 |
TRP channels in glia: therapeutic potential?
Mark Dallus, Professor in cellular neuroscience, University of Reading
|
12:40 - 13:10 |
Functional Phenotypic Models for Amyotrophic Lateral Sclerosis with human iPSC Motor derived Neurons
Olaf Schroder, CEO, Neuroproof, Germany
|
13:10 - 13:40 |
Lunch and Poster Presentation | One-to-One Networking Meetings
|
13:40 - 14:40 |
MODELLING NEUROLOGICAL DISEASES USING IPSC-DERIVED NEURAL CELLS |
Use of human stem cell models of neurological disease to advance drug discovery
Clare Jones, Chief Scientific Officer, Talisman therapeutics
|
14:40 - 15:10 |
Enabling precision medicine using human iPSC models and clinical research
Zameel Cader, Professor of Neuroscience and Neurology, University of Oxford
|
15:10 - 15:40 |
Cutting-edge iPSC platform at UCB for neurology indications
Martine Geraerts, Director Cell biology, In-vitro Pharmacology, UCB Pharma
|
15:40 - 16:10 |
Evening Refreshments and Poster Presentation | One-to-One Networking Meetings
|
16:10 - 16:50 |
Human neuronal networks on micro-electrode arrays are a robust tool to study disease phenotype in vitro
Monica Frega, Assistant Professor, University of Twente
|
16:50 - 17:20 |
Panel Discussion: Experimental models in vitro: barriers and challenges to reproduce the complexity of the brain.
Marie Christine Pardon, Assistant Professor in Translational Neuroscience, University of Nottingham
Clare Jones, Chief Scientific Officer, Talisman therapeutics
Zameel Cader, Professor of Neuroscience and Neurology, University of Oxford
Monica Frega, Assistant Professor, University of Twente
Alan Palmer, Chief Executive Officer, Elixa MediScience, UK
|
17:20 - 17:50 |
Closing Remarks from the Chairperson
|
17:50 - 18:00 |
Drinks Reception & Networking
|
18:00 - 18:00 |
End of Day 1
|
18:00 - 18:00 |